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T-cell responses to the immediate-early 1 (IE-1) protein of human cytomegalovirus 
(HCMV) are associated with protection from viral disease. Thus, IE-1 is a promising target 
for immunotherapy. CD8 T-cell responses to IE-1 are generally strong. In contrast, CD4 
T-cell responses to IE-1 were described to be comparatively infrequent or undetectable 
in HCMV carriers, and information on their target epitopes and their function has been 
limited. To analyze the repertoire of IE-1-specific CD4 T cells, we expanded them from 
healthy donors with autologous IE-1-expressing mini-Epstein–Barr virus-transformed 
B-cell lines and established IE-1-specific CD4 T-cell clones. Clones from seven out 
of seven HCMV-positive donors recognized endogenously processed IE-1 epitopes 
restricted through HLA-DR, DQ, or DP. Three to seven IE-1 epitopes were recognized per 
donor. Cumulatively, about 27 different HLA/peptide class II complexes were recognized 
by 117 IE-1-specific clones. Our results suggest that a highly diversified repertoire of 
IE-1-specific CD4 T cells targeting multiple epitopes is usually present in healthy HCMV 
carriers. Therefore, multiepitope approaches to immunomonitoring and immunotherapy 
will make optimal use of this potentially important class of HCMV-specific effector cells.
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inTrODUcTiOn
Persistent infection with human cytomegalovirus (HCMV) is widespread in healthy humans (1). 
Control of viral replication and disease is believed to critically depend on HCMV-specific T cells (2). 
In transplanted patients whose virus-specific T-cell response is impaired, HCMV can cause severe 
and potentially fatal disease (3). Likewise, the danger of harmful congenital infection is increased 
when the mother acquires HCMV for the first time during pregnancy (4). Reconstitution of HCMV-
specific T cells by adoptive transfer is associated with control of HCMV infection and disease, in 
particular in the situation after allogeneic stem cell transplantation where a compatible donor of 
HCMV-specific T cells is available (5). Although some approaches to adoptive T-cell transfer primar-
ily aim at reconstituting HCMV-specific CD8 T cells (6, 7), it appears that HCMV-specific CD4 T 
cells play an important role in therapeutic success (5, 8).
Many HCMV antigens can be targets of virus-specific T cells (9). Two of these, the virion tegu-
ment phosphoprotein pp65 and the immediate-early protein IE-1, have been in the focus of in vitro 
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studies as well as human T-cell therapy, since they are dominant 
targets of the virus-specific CD8 T-cell response (10, 11). Since 
IE proteins are the first to be expressed in viral reactivation and 
orchestrate subsequent virus replication, it appears plausible that 
IE antigen-specific T cells may be of particular importance in anti-
viral control. Accordingly, experiments with murine CMV have 
demonstrated that IE-specific CD8 T cells protect from disease 
(12, 13) and inhibit viral replication by sensing of reactivation in 
its first stage (14). Human T-cell responses to IE-1 have seemed 
more enigmatic. Compared with pp65-specific T cells, IE-1-
specific CD8 T cells are associated with superior protection from 
viral disease in transplant patients (15, 16). Paradoxically, IE-1-
specific CD8 T cells were found to recognize infected cells in vitro 
much less well than T cells specific for structural antigens, due to 
interference by HLA-modulating viral proteins (17). We recently 
resolved this apparent contradiction by showing that certain HLA 
allotypes are resistant to downregulation by viral immunoevasins 
and thus present IE-1 epitopes that are well recognized by strongly 
immunodominant populations of CD8 T cells (18, 19).
The general importance of IE-1-specific CD4 T cells has been 
unclear, in particular because of their relative rarity. Already in 
1988, such T cells were identified in healthy HCMV carriers (20), 
and several HLA-DR-restricted T-cell epitopes of IE-1 have been 
characterized (21–23). However, employing different techniques 
to measure IE-1-specific CD4 T cells, several studies identified 
them in only about one-third of HCMV-positive donors (9, 22, 
24), whereas others did not detect them at all (25, 26).
These findings raised the question of whether IE-1-specific 
CD4 T cells are a regular component of the HCMV-specific T-cell 
response and can be expected to mediate antiviral functions in 
a majority of healthy carriers or patients after successful immu-
notherapy. Therefore, we expanded such T cells from healthy 
HCMV-positive donors by stimulation with autologous B cells 
carrying a mini-Epstein–Barr virus (mini-EBV) expressing IE-1. 
We established a series of IE-1-specific CD4 T-cell clones and 
studied their epitope specificities and functions.
MaTerials anD MeThODs
ethics statement and Donors
Mononuclear cells from standard blood donations by anony-
mous healthy adult donors were obtained from the Institute for 
Transfusion Medicine, University of Ulm, Germany. The institu-
tional review board (Ethikkommission, Klinikum der Universität 
München, Grosshadern, Munich, Germany) approved this 
procedure. All work was conducted according to the principles 
expressed in the Helsinki Declaration.
HLA class II types of the seven donors who were analyzed for 
their IE-1-specific T-cell repertoire are provided in Table 1. High-
resolution HLA typing was performed by PCR-based methods 
(IMGM, Martinsried, Germany). The HCMV IgG serostatus was 
determined (Max von Pettenkofer Institute, Munich, Germany).
B cells, Plasmids, and Peptides
Standard cell culture medium was RPMI1640 (Invitrogen) with 
10% fetal calf serum (Invitrogen), penicillin (100 U/mL), strepto-
mycin (100 g/mL, Invitrogen), and 100nM sodium selenite (ICN). 
Mini-lymphoblastoid cell lines (mini-LCLs) stably expressing 
HCMV IE-1 (18) were generated as described (27) by infection 
of PBMCs with packaged recombinant mini-EBV carrying the 
HCMV IE-1 gene from HCMV strain AD169 under the SV40 
early promoter. Mini-LCLs lacking expression of a heterologous 
protein were analogously generated. CD40-stimulated B-cell cul-
tures were established and maintained as described (28). DG75 
cells were from ATCC. Sequences coding for HLA class II chains 
were amplified from PBMCs or LCLs and cloned into pCMV-
cyto. Peptides were synthesized to >70% purity by JPT (Berlin), 
resuspended in 100% dimethyl sulfoxide (DMSO), and stored 
at −20°C. To identify IE-1 peptides recognized by T cells, we 
used a peptide library of 120 peptides with a length of 15 amino 
acids and an overlap of 11 amino acids, which covered the entire 
491-amino acid protein sequence of IE-1 from HCMV strain 
AD169. To facilitate screening, peptides were distributed to 12 
“vertical” subpools (subpools 1–12) and 10 “horizontal” subpools 
(subpools 13–22), in analogy to the procedure described for pp65 
(29). Subpool 23 contained nine additional 15-meric peptides 
from IE-1 that covered selected sequence variants appearing 
in HCMV strains Toledo and TB40. Protein sequences follow 
GenBank entries FJ527563 (AD169 substrain varUC, complete 
genome), GU937742 (strain Toledo, complete genome), and 
KF297339 (strain TB40/E clone Lisa, complete genome).
T cells
IE-1-specific polyclonal T-cell lines were prepared by restimula-
tion of PBMCs from HCMV-seropositive donors with irradiated 
autologous IE-1-expressing mini-LCLs, as previously described 
for pp65 (30). Per well of a 24-well plate, 2 million PBMC and 
50,000 irradiated mini-LCL (50 Gy) were cocultivated in 2 mL 
medium. On day 10 and then after intervals of 7 days, cells were 
pooled, counted, and replated at 1 million cells in 2 mL medium 
TaBle 1 | hla class ii types of T-cell donors.
Donor hla-DrB1 hla-DrB3/4/5 hla-DQa1 hla-DQB1 hla-DPa1 hla-DPB1
ALT *0401, *1501  4*0103, 5*0101 *0102, *0303 *0301, *0602 *0103, *0201 *0401, *1101
ARZ *0403, *1501 4*0103, 5*0101 *0102, *0301 *0302, *0602 *0103, – *0201, *0301
AJU *0701, *1301 3*0202, 4*0101 *0103, *0201 *0202, *0603 *0103, – *0401, *2001
F61 *0102, *0701 4*0101 *0101, *0201 *0202, *0501 *0103, *0201 *0402, *1401
F63 *0101, *0803 None n.d. *03, *05 n.d. *0401, –
F64 *0701, *1301 3*0101, 4*0101 *0103, *0201 *0202, *0603 *0103, *0201 *0201, *1101
F65 *1454, *1501 3*0202, 5*0101 *0101, *0102 *0503, *0602 *0103, – *0201, *0301
n.d., not determined.
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per well, adding freshly irradiated mini-LCL cells as stimulators at 
an effector–stimulator ratio of 4:1. Cells were re-fed or expanded 
at least once between stimulations. From day 15 onward, culture 
medium was supplemented with rIL-2 (50–100 U/mL; Proleukin, 
Novartis). After 6–8  weeks of cultivation, CD4 T cells were 
positively isolated using CD4 Microbeads (Miltenyi Biotec) 
and submitted to limiting dilution to obtain T-cell clones. For 
limiting dilution, T cells (0.7 or 2.5 cells/well) were seeded into 
round-bottom 96-well plates (200 μL/well) in medium supple-
mented with 1,000 U/mL rIL-2, 1 × 105/mL irradiated (50 Gy) 
autologous IE-1-expressing mini-LCLs, and 1.5 ×  106/mL of a 
mixture of irradiated (50  Gy) allogeneic PBMCs from at least 
three different donors. Outgrowing T-cell clones were expanded 
in round-bottom 96-well plates by restimulating every 2 weeks 
under the same conditions. For analysis by flow cytometry, T 
cells were stained with CD4-FITC and CD8-APC (BioLegend) 
for 20 min on ice, washed with PBS + 2% FCS, and analyzed on 
a BD Biosciences FACSCalibur flow cytometer. Data analysis was 
performed using FlowJo 9.4.11 software (Tree Star).
T-cell effector assays
PBMCs were analyzed for specific IFN-γ secretion in ELISpot, 
T-cell clones in IFN-γ ELISA. Antigenic peptides were used at 
final concentrations of 5 μg/mL per peptide when using single 
peptides or subpools of up to 12 peptides, except when indicated 
otherwise. IFN-γ ELISpot analyses (Mabtech, Nacka, Sweden) 
were performed in 96-well MultiScreen HTC Filter Plates 
(Millipore). After antibody coating of the wells, 200,000 PBMCs 
were distributed to each well, directly loaded with antigenic 
peptide, and incubated in a total of 200  μL medium per well 
for 16–18  h at 37°C and 5% CO2. After counterstaining with 
biotinylated secondary antibody and streptavidin-AP, spots were 
developed using the AP Conjugate Substrate Kit from Bio-Rad 
and visually counted after scanning. For ELISPOT analysis of cul-
tivated polyclonal T cells, 2,000–10,000 T cells were cocultivated 
with 50,000 CD40-stimulated B cells preloaded with peptides, 
and incubated and processed as above.
For initial screening of T-cell clones for IE-1 specificity, 
10-μL aliquots of cloning wells (containing approximately 
2,000–10,000 T cells) were coincubated with autologous 
ctrl-mini-LCL, IE-1-mini-LCL, and CD40-stimulated B cells 
(50,000 cells/well) in 200 μL/well in V-bottom 96-well plates at 
37°C and 5% CO2 overnight, and supernatants were analyzed 
in IFN-γ ELISA (Mabtech, Nacka, Sweden). For determination 
of peptide specificity, T cells (10,000 cells/well) were incubated 
overnight with CD40-stimulated B cells (20,000 cells/well) in 
the presence of peptides (5 μg/mL per peptide) and analyzed 
in IFN-γ ELISA.
For determination of HLA restriction using inhibitory anti-
bodies, T cells (10,000 cells/well) were incubated overnight with 
IE-1-expressing mini-LCLs (20,000 cells/well) in the presence 
of unlabeled purified antibodies specific for HLA-DR (clone 
L243, BioLegend), HLA-DQ (clone SPV-L3, AbD Serotec), or 
HLA-DP (clone B7/21, Abcam). For further determination of 
HLA restriction, T cells (10,000 cells/well) were incubated with 
control mini-LCLs and IE-1 mini-LCLs (20,000 cells/well) from 
a panel of 15 HLA-typed donors. After overnight incubation in 
V-bottom 96-well plates, supernatants were analyzed by ELISA. 
For determination of HLA restriction by transfection of HLA-
encoding plasmids, 5  million DG75 cells were electroporated 
with a maximum of 20 μg of plasmid DNA (DRA- and DRB-
coding sequences separately cloned into the pCMVcyto plasmid) 
in a Bio-Rad Gene Pulser (settings 230  V, 975 μF) in a 4-mm 
wide cuvette. Thereafter, cells were cultivated overnight, loaded 
with peptide, cocultivated together with T-cell clones over the 
following night (50,000 T cells and 50,000 transfected DG75 cells 
in 200 μL per V-bottom well), and supernatants were analyzed in 
IFN-γ ELISA.
resUlTs
To enrich IE-1-specific T cells from peripheral blood from 
healthy HCMV carriers, we used a mini-EBV carrying the 
HCMV IE-1 gene under control of the SV40 early promoter (18). 
IE-1-expressing lymphoblastoid cell lines (mini-LCLs) were 
established from seven healthy HCMV IgG-positive adults, and 
PBMCs from these donors were restimulated with the autologous 
IE-1 mini-LCL for 6–8  weeks. The resulting polyclonal T-cell 
lines were heavily dominated by CD8+ T cells (18) but also con-
tained a minor component of CD4+ T cells (3% on average). By 
immunomagnetic separation, we enriched this CD4+ component 
to an average of 97% (Figure  1A). To test whether these cells 
contained IE-1-specific CD4+ T cells, we stimulated them in an 
IFN-γ ELISPOT assay with a peptide library that represented the 
complete IE-1 sequence in the form of 15-mer peptides with an 
overlap of 11 amino acids, distributed to 23 different subpools. 
For each of the seven donors, the enriched CD4+ T cells recog-
nized a subset of IE-1 peptide subpools, often others than were 
recognized by CD8+ (CD4-depleted) T cells from the same donor, 
and often ones that elicited no detectable reactivity from PBMC 
ex vivo (Figure 1B).
From these seven CD4-enriched T-cell cultures, we estab-
lished T-cell clones by limiting dilution. At least 100 CD4+ 
T-cell clones from each donor were tested for their capability to 
recognize endogenously processed IE-1 epitopes, by comparing 
their recognition of autologous IE-1-expressing mini-LCLs, 
IE-1-negative mini-LCLs, and CD40-activated B cells. An 
example of such an analysis is shown in Figure 2A. Only T-cell 
clones with a clear IE-1-specific reactivity pattern (at least five-
fold recognition of IE-1 mini-LCLs over controls) were selected 
for further study. A clear recognition pattern of IE-1 peptide 
subpools was obtained for a majority of these CD4+ T-cell 
clones, which allowed to determine their core peptide epitope 
with an 11- to 15-amino acid precision (Figure 2B). To narrow 
down their HLA restriction, we used inhibitory antibodies to 
HLA-DR, HLA-DQ, or HLA-DP (Figure 2C). HLA restriction 
was further specified by determining reactivity of T-cell clones 
to a panel of HLA-typed mini-LCLs. In the example shown in 
Figure 2D, HLA-DQ-restricted T-cell clone 223 from donor F61 
recognized only the IE-1 mini-LCLs from three of 15 donors. 
The only HLA-DQA and DQB chains that were shared by these 
three donors but not others in the panel were DQA1*0201 and 
DQB1*0202. Thus, these were concluded to be the HLA class II 
chains presenting the epitope.
FigUre 1 | enrichment of ie-1-specific cD4 T cells. (a) After 6–8 weeks of restimulation with the autologous IE-1 mini-LCL, T-cell cultures were 
immunomagnetically separated into CD4+ and CD4− fractions, and the purity of these fractions was analyzed by flow cytometry. Results for two exemplary donors 
are shown. (B) PBMCs ex vivo and the separated CD4-enriched (CD4+) and CD4-depleted (CD8+) fractions of IE-1 mini-LCL-stimulated T-cell cultures were tested 
for their reactivity to IE-1 peptides in an IFN-γ ELISPOT assay. A peptide library covering the entire IE-1 protein sequence from HCMV strain AD169 plus some 
sequence variants from strains Toledo and TB40 was used for the stimulation of specific T cells in this assay. PBMCs were stimulated with peptide only, CD4+ and 
CD8+ fractions were stimulated with CD40-activated B cells loaded with peptides. Results are shown for two representative donors.
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These analyses of IE-1-specific CD4 T-cell clones showed that 
each of our seven donors harbored in their peripheral blood 
CD4 T cells specific for multiple IE-1 epitopes that were endog-
enously processed and presented. A median of five epitopes 
(range 3–7) per donor was identified (Figure 3A). Cumulatively, 
the CD4+ T cells from these seven donors recognized approxi-
mately 27 different epitopes from IE-1 (Figure 3B). T cells that 
recognized HLA-DR-restricted epitopes were found in six of 
seven donors, HLA-DQ-restricted epitopes in four donors, 
and HLA-DP-restricted epitopes in five. The most dominant 
FigUre 2 | Determination of specificity.  
 (Continued)
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(a) In a first screen, recognition of endogenously processed IE-1 epitopes by CD4+ T-cell clones was determined by evaluating IFN-γ secretion (ELISA) in response 
to three different autologous target cell lines: an IE-1-expressing mini-LCL, an IE-1-negative mini-LCL (ctrl-mLCL). and non-infected, CD40-stimulated B cells. As an 
example, the panel shows the reactivity of the first 32 T-cell clones from donor F65. Only CD4 T-cell clones with a clear preference for the IE-1 mini-LCL were 
studied further. (B) IE-1 epitope specificity was determined by evaluating reactivity to the 23 subpools of the IE-1 peptide library. Peptides were loaded onto 
autologous mini-LCLs or CD40-stimulated B cells. The analysis of four representative T-cell clones is shown. (c) Restriction through the major subclasses of HLA 
class II was assessed by measuring blockade of IFN-γ secretion in the presence of specific antibodies to HLA-DR, -DQ, or -DP. Results are shown for three 
exemplary CD4+ T-cell clones. (D) Individual restricting HLA class II allotypes were deduced from the pattern of IFN-γ secretion in response to a panel of mini-LCLs 
from various HLA-typed donors, always including the IE-1-expressing mini-LCL (IE) and the IE-1-negative mini-LCL (“c” for control).
FigUre 2 | continued
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single epitope-specific response  –  in terms of the number of 
clones that could be established  –  was HLA-DR-restricted in 
five donors, DP-restricted in one (F61), and DQ-restricted in 
one donor (F65). Several epitopes were shared between donors 
(Figure 3B).
The largest number of epitopes restricted through the same 
HLA allotype was found for DRB1*1301, which was carried by 
two of the donors and presented a total of nine different epitopes, 
according to their patterns of reactivity to peptide subpools. 
Five of these epitopes were located in region 85–111 of IE-1 and 
partially overlapping, which raises the possibility that some of 
these epitopes were not distinct, but recognized by different T-cell 
clones with different requirements for flanking residues outside 
the core epitope. The other four DRB1*1301-restricted epitopes 
were all non-overlapping and located in other regions of IE-1 
(Figure 3B). Of note, two overlapping peptides (representing one 
or two epitopes) in the same 85–111 region were recently identi-
fied as being presented by DRB1*1301 (22). Determination of 
the precise number of distinct epitopes in this region will require 
additional analyses with potential minimal peptides at limiting 
dilution or by HLA/peptide tetramer staining (22).
Some largely overlapping epitopes were presented by more 
than one HLA allotype. A largely overlapping stretch in the 
221–239 region was presented to T-cell clones from donor 
ALT either by HLA-DQ or by HLA-DP. Another epitope 
(CSPDEIMAYAQKIFKILDE) was recognized by a DRB1*1501-
restricted T-cell clone from donor ALT and by a DRB1*1301-
restricted clone from donor F64.
HLA-DP-restricted T-cell clones tended to recognize pep-
tides that were presented by more than one HLA-DP allotype. 
Three donors who carried one member of a related group of 
DPB1 alleles (*0301, *1401, or *2001) had T cells specific for the 
SVMKRRIEEICMKVFAQYI epitope, and such clones recog-
nized this peptide not only on the autologous HLA-DP molecule 
but also on other HLA-DP allotypes inside or outside that group. 
DPB1 alleles *0301, *1401, and *2001 are closely related, with a 
maximum difference of two amino acid polymorphisms (31), 
which makes such a crossrecognition plausible.
Certain negative conclusions were also suggested by these 
results. Three donors (AJU, F61, and F64) were carriers of the 
DRB1*0701 allotype, and our results ruled out a restriction 
through this allotype for all clones from these donors. Therefore, 
HLA-DRB1*0701 appears less likely to present IE-1 epitopes, 
and to our knowledge no such epitopes have been described by 
others. However, DRB1*0701 is in linkage disequilibrium with 
DQA1*0201/DQB1*0202 as described (32), and thus carriers of 
this haplotype can instead target IE-1 through HLA-DQ-restricted 
CD4 T cells, as seen for two of our three donors with this haplo-
type (Table 1; Figure 3B).
An overview of the distribution of CD4 T-cell epitopes within 
the IE-1 protein sequence, color-coded by donor, is provided 
in Figure 4. Epitopes were not uniformly distributed, but were 
concentrated in certain regions of the protein. The concentration 
was the highest in region 193–239. Epitopes in this region were 
recognized by five of seven donors and had six distinct HLA 
restrictions, counting the promiscuous HLA-DP restriction of the 
SVMKRRIEEICMKVFAQYI epitope only once. Regions of high 
epitope density could be of particular interest for immunologic 
therapy or monitoring.
We performed a more detailed analysis of the HLA-
DRB5*0101-restricted epitope YRNIEFFTKNSAFPKTTNG at 
position 209–227. The HLA-DRB1*1501/DRB5*0101 haplotype 
is of high frequency in persons of European and Asian descent (33, 
34). Responses to this epitope were detected in all three donors 
with this haplotype, and in one of one additional haplotype car-
rier who was screened only for this epitope. Since the two DRB 
genes of this haplotype are in strong linkage disequilibrium, it 
was necessary to determine the restricting molecule by a molecu-
lar approach. An analysis of IFN-γ secretion by T-cell clones in 
response to peptide-loaded, single HLA-transfected DG75 cells 
(Figure  5A) showed that the 209–227 epitope was restricted 
through DRB5*0101, whereas the 241–259 epitope was restricted 
through DRB1*1501 (compare Figure 3B). We also determined 
the minimal epitope within the 209–227 region by analyzing the 
response to various subsequences of different length (Figure 5B). 
Since, at a low peptide concentration of 1nM, a 13-mer peptide 
EFFTKNSAFPKTT (position 213–225) was maximally recog-
nized, whereas the two contained 12-mers elicited an equally 
reduced response and the central 11-mer only a weak response, 
we operationally defined the 13-mer to be the functional mini-
mal epitope. This epitope, with its core motif FxxNxxxxK, is in 
relatively good accordance with a previously described motif of 
DRB1*0501 ligand peptides (35). So far, we were unable to detect 
specific IFN-γ-secreting CD4 T cells responsive to this epitope by 
ELISPOT ex vivo in peripheral blood, which suggests that their 
precursor frequency is below one in 50,000 cells.
To analyze whether other epitopes identified here were in 
accordance with expectations regarding their HLA restriction, 
we used an advanced HLA class II binding prediction algorithm, 
NetMHCII 2.2 (36), to screen the IE-1 sequence for areas of 
predicted high binding affinity (Figure  6). The region of IE-1 
with the highest predicted binding affinity to DRB5*0101 was 
precisely located at the position of the EFFTKNSAFPKTT epitope 
(Figure  6A). The DRB1*1501-restricted epitope 241–259 was 
FigUre 3 | cD4 T-cell epitopes in ie-1 and their hla restrictions. (a) Overview of the number and HLA restriction of different IE-1 epitope specificities per 
donor. (B) Full listing of epitopes and their HLA restrictions. Each T-cell clone recognized either a single 15-mer peptide or two adjacent peptides, covering 19 amino 
acids of the IE-1 sequence. Whenever two adjacent peptides were recognized with similar intensity (lower reactivity was greater than 50% of higher reactivity), their 
11 amino acid overlap is shown in boldface; in other cases (lower reactivity between 10 and 50% of higher reactivity), the preferentially recognized 15-mer sequence 
is shown in boldface. Epitopes were considered distinct when their patterns of peptide recognition differed, even if they partially overlapped. Epitopes recognized by 
CD4 T-cell clones from more than one donor are highlighted in color. Entries in red text were verified in effector assays using transfection of single recombinant HLA 
molecules. Non-autologous HLA restrictions are in parentheses. An asterisk (*) indicates that both the strain AD169 sequence and the variant sequence from Toledo 
or TB40 were recognized. A double asterisk (**) indicates recognition of the AD169 sequence only.
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FigUre 4 | Distribution of cD4 T-cell responses and epitopes within the ie-1 protein sequence. Each bar represents an epitope-specific response in one 
donor. Different donors are represented by different colors. Thick bars represent an epitope-specific response of more than 20% of a donor’s T-cell clones, thin bars 
responses of 20% of clones or less.
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located in one of four regions with predicted high binding affinity. 
Prediction for DRB1*1301 was not available in NetMHCII 2.2, 
so we analyzed prediction for DRB1*1302, but agreement with 
IE-1 epitopes was limited. The DRB3*0202/*0101-presented 
epitope at position 201–219 was not predicted by the algorithm 
for DRB3*0101. Available algorithms for specific HLA-DQ and 
HLA-DP heterodimers were in reasonably good agreement with 
most of our identified epitopes (Figure 6B).
DiscUssiOn
Here, we show that IE-1-specific CD4 T cells can regularly be iso-
lated from HCMV-positive donors of various HLA backgrounds. 
Although we studied a limited group of only seven donors, our 
robust detection of several specificities in each of these suggests 
that IE-1-specific CD4 T cells participate in antiviral T-cell 
responses in all or a majority of healthy carriers. CD4 T cells 
recognized IE-1 peptides presented by various HLA-DR, -DQ, 
or -DP allotypes, and each donor had T cells that were restricted 
through at least two of these three subclasses of HLA class II. A 
median of five (range 3–7) epitopes was recognized by T cells 
from each donor. Thus, IE-1-specific CD4 T-cell responses are 
widespread, diversified, and restricted by a wide range of different 
HLA class II allotypes. This observation provides arguments in 
favor of including IE-1 as a target antigen in immunotherapeutic 
approaches, such as multiepitope-specific adoptive T-cell transfer 
(37), with the intention to reconstitute specific CD4 as well as 
CD8 T cells. Our dataset will enable more comprehensive and 
precise analyses of the role of IE-1-specific CD4 T cells in immu-
nocompromised patients, for example, by sensitive detection with 
HLA/peptide multimers (22).
Our results show that healthy HCMV-positive donors harbor 
IE-1-specific T cells even if they may not be easily detectable ex 
vivo with standard analytic methods. A seminal study identified 
proliferative responses to baculovirus-expressed IE-1 in about 
60% of HCMV-positive donors (21). However, several subse-
quent studies have reported lower rates: IE-1-specific CD4 T 
cells were identified only in about one-third of HCMV carriers 
by measuring proliferation to IE-1-containing cell lysates (24) 
or by intracellular cytokine staining after peptide stimulation (9, 
22). Other comprehensive studies employing peptide stimula-
tion in connection with ELISPOT (25) or intracellular cytokine 
staining (26) did not identify IE-1-specific CD4 T cells in any 
of the donors studied or identified them only rarely (38). Like 
these researchers, we found it difficult to detect and quantify 
IE-1-specific CD4 T cells ex vivo by ELISPOT, presumably due to 
their low frequency, which prompted us to use specific expansion 
in cell culture in order to access these T cells for closer study. Since 
T-cell responses to other widespread human viruses that are well 
controlled by specific immunity can nonetheless elude ex vivo 
quantification but become detectable after expansion (39), it may 
not be surprising that the same is true for certain constituents of 
HCMV-specific T-cell immunity. Because T cells specific for a 
subset of antigens within a herpesvirus-specific T-cell repertoire 
may selectively home to specific tissues (40), low frequencies of 
IE-1-specific CD4 T cells in peripheral blood may not exclude an 
important role of these T cells in control of infection.
Studies on the functional role of IE-1-specific CD4 T cells are 
now easier than before, since with our present work a sufficient 
number of epitopes with different HLA restrictions has been 
identified to cover a majority of human HLA phenotypes. The 
chance that an HLA haplotype in a central European popula-
tion contains at least one of the alleles DRB1*1301, DRB1*1501, 
DRB5*0101, DRB3*0101, DRB3*02, or DQB1*02 is 41%, 
resulting in a probability of 65% or higher that one or more of 
them appear in an HLA phenotype (41). This estimation still 
disregards HLA-DP, which will make an additional contribution 
to population coverage by known IE-1 epitopes, especially since 
we observed that T cells recognized the same epitope on a group 
of several mutually related HLA-DP allotypes. However, the 
HLA allotypes studied here are not only relevant for donors of 
European descent. HLA-DRB1*1501 and DRB5*0101 are among 
the most frequent HLA-DRB allotypes in East Asians as well as 
Caucasians (34, 42). HLA-DPB1*0201 is the second most fre-
quent DPB1 allele both in East Asians and Caucasians (34, 43), 
and DRB3*0202 is present in Americans of African, European, 
and Asian descent at similar gene frequencies between 0.2 and 
0.3 (42). Thus, the present set of epitopes will be useful for 
immunomonitoring or immunotherapy of patients of various 
ethnicities.
We identified approximately 27 different epitopes in total, but 
the exact number may be somewhat lower, since five discernable 
DRB1*1301-restricted epitope recognition patterns were derived 
from the region at amino acids 85–111 of IE-1, and some of these 
FigUre 5 | analysis of an hla-DrB5*0101-restricted epitope. (a) HLA restriction was molecularly defined by testing the reactivity of specific CD4 T-cell clones 
against DG75 cells that were transiently transfected with plasmids encoding the DRA chain and the indicated DRB chain, and transfectants were loaded with 
specific peptide where indicated. Recognition of peptide-loaded mini-LCL served as functional control. (B) Reactivity in response to titrated peptides representing 
various subsequences of the antigenic region. Peptides were loaded on autologous CD40-activated B cells, coincubated with clonal T cells overnight, and response 
was measured in an IFN-γ ELISA.
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five functionally defined epitopes may not in fact correspond 
to distinct minimal epitopes. Moreover, two HLA-DPB1*0201-
restricted specificities from donor ARZ recognized overlapping 
epitopes in the 197–211 region, and two DR-restricted epitopes 
from donors ALT and F65 overlap in the 113–131 region. Thus, 
our estimated lower limit of the number of distinct epitopes 
identified in our set of donors is 21. On the other hand, we can-
not exclude the possibility that some of the functional epitopes 
identified in this study contain more than one minimal epitope. 
Since several epitope specificities were represented by only a 
single T-cell clone in our panel, and our analysis covered only a 
limited part of the human HLA class II repertoire, our analysis 
very likely underestimates the true diversity of the IE-1-specific 
CD4 T-cell response.
We have demonstrated that IE-1 epitopes can be restricted 
through all subclasses of HLA class II molecules, HLA-DR, 
-DQ and -DP, have enlarged the number of known HLA-DR-
restricted epitopes, and have identified IE-1 epitopes restricted 
FigUre 6 | comparison of hla binding predictions and confirmed epitopes. The NetMHCII 2.2 algorithm was used to calculate predicted binding affinities 
(nM) along the IE-1 sequence for those allotypes that were restriction elements of epitopes identified in this study. Curves show predicted affinities in nanomolar for 
each 15-mer whose N terminus is located at the IE-1 amino acid position indicated on the x-axis. “L” shapes represent confirmed IE-1 epitopes. The horizontal arm 
of each “L” indicates the position of reference on the x-axis, the vertical arm points at the position of reference in the prediction curves. One epitope with two 
possible HLA restrictions is represented as a pair of dashed “L” shapes. (a) Prediction for HLA-DR allotypes and confirmed DR-restricted epitopes. Since prediction 
for HLA-DR*1301 was not available in NetMHCII, HLA-DR*1302 is shown instead. (B) Prediction for available HLA-DQ and DP allotypes that match epitopes 
identified in this study, and the position of corresponding DQ- or DP-restricted epitopes.
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through HLA-DQ and HLA-DP for the first time. Some of the 
HLA-DR-restricted epitopes recognized by our T-cell clones have 
been described before. The 85–111 region of IE-1, where we have 
identified several DRB1*1301-restricted specificities, coincides 
with a previously identified DR13-restricted epitope in one donor 
(23), and in the same IE-1 region one or possibly two overlapping 
DRB1*1301-restricted epitopes recognized by another donor 
have been found (22). Our DRB5*0101-restricted epitope at 
position 213–225 coincides with a previously described epitope 
of the same restriction that was recognized by specific T cells in 
four of four carriers of this allele (22, 44), and the same region 
was dominantly targeted by CD4 T cells in a carrier of HLA-DR2 
(21), which is compatible with its DRB5*0101 restriction. Thus, 
responses to these epitopes have so far been consistently found in 
several independent studies in all donors with the respective HLA 
phenotypes. These epitopes may tend to elicit responses that are 
particularly dominant among the IE-1-specific T-cell repertoire, 
which is indirectly corroborated by the relatively high number of 
corresponding T-cell clones that we obtained from our donors. 
Thus, our data, together with those of others, provide evidence 
for the existence of conserved immunodominance hierarchies 
among IE-1-specific CD4 T cells. Nonetheless, the CD4 T-cell 
repertoire responding to IE-1 is clearly more diversified and less 
influenced by immunodominance of individual epitopes than the 
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CD8 T-cell repertoire, since IE-1-specific CD8 T cells in healthy 
HCMV carriers recognize, on average, fewer than two epitopes 
per donor (38).
While the role of IE-1-specific CD4 T cells in control of disease 
has been difficult to study due to their low frequency, there is con-
vincing evidence that HCMV-specific CD4 T cells contribute to 
protection from disease after solid organ and stem cell transplan-
tation (45–47). Moreover, strong therapeutic effects were shown 
in a study on adoptive transfer of predominantly CD4-positive 
HCMV-specific T cells after stem cell transplantation (8). In the 
murine CMV model, CD4 T cells are indispensable to control of 
viral replication in salivary glands (48, 49), and in the absence of 
CD8 T cells antiviral protection requires CD4 T cells (50).
Whether IE-1-specific T cells (CD8 or CD4) are of superior 
importance in control of infection has remained more controver-
sial. For different human transplant situations, it was described 
that IE-1-specific T-cell responses, in contrast to T cells specific 
for the HCMV structural antigen pp65, are associated with con-
trol of HCMV disease (15, 16). However, others have observed 
an association of pp65-specific T cells with control of HCMV 
(51, 52), and therapeutic transfer of pp65-specific T cells was 
associated with reduction or clearance of manifest infection (5, 
6). Since HCMV interferes with antigen presentation to T cells 
in an HLA class I allotype-specific manner (18, 53), individual 
epitopes from the same antigen may strongly differ in the efficacy 
of their presentation to CD8 T cells (18, 19). Thus, which HCMV 
proteins assume the role of protective antigens may depend 
on the HLA allotypes that are available in a particular HCMV 
carrier. Information of this kind has so far been lacking for IE-1-
specific CD4 T cells, but identification of their target epitopes 
makes it now possible to undertake precise analyses of their role 
in combating infection and disease and to explore their function 
in adoptive T-cell therapy.
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